Positron (OTCMKTS:POSC) Trading 0.4% Higher - Still a Buy?

Key Points

• Positron shares rose 0.4% in Friday trading, reaching an intraday high of $1.84 and last trading at $1.80, with volume notably below average at 21,797 shares.
• The stock remains around key technical levels, with a 50-day moving average of $1.96 and a 200-day moving average of $1.77, while the company carries a market cap of about $59.13 million.
• Positron’s latest earnings showed continued weakness, posting EPS of -$0.22 on just $0.11 million in revenue, alongside very high negative profitability metrics.

Positron Corp. (OTCMKTS:POSC - Get Free Report)'s share price traded up 0.4% during trading on Friday . The company traded as high as $1.84 and last traded at $1.80. 21,797 shares changed hands during trading, a decline of 50% from the average session volume of 43,890 shares. The stock had previously closed at $1.7920.

Positron Trading Up 0.4%

The business has a fifty day moving average of $1.96 and a 200 day moving average of $1.77. The company has a market capitalization of $59.13 million, a PE ratio of -5.29 and a beta of 0.15.

Positron (OTCMKTS:POSC - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported ($0.22) EPS for the quarter. The firm had revenue of $0.11 million for the quarter. Positron had a negative net margin of 1,975.71% and a negative return on equity of 593.80%.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.